COMPANY BIOS FOR THE 2012 SUMMIT
Presenting Companies Bactiguard »
DiaGenic »
Ericsson »
Karolinska Development »
Kindstar Global »
Medicine in Need »
Moberg Derma »
Oral Care »
Serendipity Innovations »
Access Health International »
AliveCor »
AroCell »
BioLamina »
Diabetes Tools »
Insulation »
MedUniverse »
PillJogger »
Q-linea »
Download Company Bios for the 2012 Summit (pdf, 320Kb) »
Top of page »
Bactiguard provides world-leading solutions preventing hospital-acquired infections - the 4th largest cause of death in the Western
world. By using the Bactiguard technology Governments can reduce
healthcare cost, lower the use of antibiotics and save lives. The
Bactiguard technology consists of an extremely thin noble metal
coating, with antimicrobial and biocompatible properties that can be
used on all sorts of medical devices. The Bactiguard coated urinary
catheter has since 1995 been used by more than 110 million patients
in the US. Today Bactiguard offers a full range portfolio within
infection prevention in the urinary tract, respiratory tract and blood
stream. Bactiguard is currently expanding its business activities to
markets, such as China, India, Europe, South America and the Middle
East.
For more information, please visit www.bactiguard.com
Top of page »
DiaGenic seeks to create value for patients, partners, and investors by developing innovative and more patient friendly methods for early detection of diseases utilizing DiaGenic's unique concept. The concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples.
DiaGenic is a world leader in identifying these gene expression signatures in peripheral blood and is focused on the development of biomarkers in the field of Alzheimer's disease and Parkinson's disease. DiaGenic's Alzheimer's disease development program includes the CE marked diagnostic test ADtect, for detection of mild to moderate Alzheimer's disease, and MCItect®which is under development for identifying patients with very early stages of Alzheimer's disease (prodromal AD).
DiaGenic's concept is protected through an extensive patent portfolio. DiaGenic promotes its products and services towards leading pharmaceutical, imaging and diagnostic companies. DiaGenic is located in Norway and listed on the Oslo Stock Exchange.
For more information, please visit www.diagenic.com
Top of page »
Ericsson is the world's leading provider of communications technology and services. We are enabling the Networked Society with efficient real-time solutions that allow us all to study, work and live our lives more freely, in sustainable societies around the world. Our offering comprises services, software and infrastructure within Information and Communications Technology for telecom operators and other industries. Today more than 40 percent of the world's mobile traffic goes through Ericsson networks and we support customers' networks servicing more than 2.5 billion subscribers. We operate in 180 countries and employ more than 100,000 people. Founded in 1876, Ericsson is headquartered in Stockholm, Sweden. In 2011 the company's net sales were SEK 226.9 billion (USD 35.0 billion). Ericsson is listed on NASDAQ OMX, Stockholm and NASDAQ, New York stock exchanges.
For more information, please visit www.ericsson.com
Top of page »
Karolinska Development aims to create value for investors, patients, and researchers by developing innovations
from world class science into products that can be sold or out-licensed with high returns. The business model
is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where
the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of
companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations
AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of
innovations. Today, the portfolio consists of 35 projects, of which 14 are in clinical development.
For more information, please visit www.karolinskadevelopment.com
Top of page »
Kindstar Globalgene Technology, Inc. (Kindstar), with sophisticated laboratory facilities in
Beijing, Shanghai, and Wuhan, is the first and largest esoteric diagnostic testing business
in China. It provides esoteric diagnostic testing services to hospitals and physicians in
every province of China. Currently, it comprises of Wuhan Kindstar Diagnostics Co., Ltd
(Headquarter of the Holding Company), Beijing Hightrust Diagnostics Co., Ltd, Beijing
Globalgene Technology Co., Ltd, Shanghai Cinpathogen Clinical and Molecular Research
Center, and Shanghai Mei Zhong Clinical Laboratory Co., Ltd.
With a service network covering more than 300 cities, Kindstar provides advanced reference
laboratory testing service for over 2000 Chinese hospitals, including 660 top-level tertiary care
hospitals. Kindstar's diagnostic services help physicians properly diagnose diseases and allow
them to develop treatment plans for patients. Kindstar has become the partner of choice to
physicians in China for advanced diagnostics in many medical specialties including hematology,
oncology, genetics, infectious diseases, and cardiovascular disease.
For more information,
please visit www.kindstarglobal.com.
Top of page »
Medicine in Need (MEND) is a 501(c)3
not-for-profit devoted
to the successful
development and manufacture of affordable
and effective
vaccines and therapies for
diseases of poverty with
characteristics that allow
their widespread use and sustainability.
We do this by incubating (and subsequently applying)
emerging and
advanced delivery
and manufacturing technologies to drug and
vaccine candidates
for diseases to make
them well-suited for the daunting
economic and logistical
constraints of the developing
world. One of the most common challenges involves "thermostability"
(eliminating
the
requirement for refrigeration), which MEND has
successfully accomplished
for a number of
vaccines including Tuberculosis vaccine, and
Rotavirus. MEND's
business model is unique
(and has been
awarded the World Economic Forum "Technology Pioneer" Award in
2011)
in that it aims to become self-funded through a unique blend
of
intellectual-property
management and partnering models that
transcend
conventional for-profit and not-for-
profit boundaries.
For more information, please visit www.medicineinneed.org
Top of page »
Moberg Derma AB (publ.)
SWEDEN
Moberg Derma (OMX: MOB), Stockholm, is a rapidly growing pharmaceutical company focusing on topical products for skin diseases. Moberg Derma's first product Nalox™(Kerasal® Nail in the U.S.) - for nail disorders - is the Nordic market leader and launch is ongoing in many markets. In the U.S., Nalox™/Kerasal® Nail has reached a top-3 sales position and is available in 20,000 sales outlets, including leading retailers Walmart, CVS, Walgreens and RiteAid.
The success of Nalox™ has enabled Moberg Derma to quickly evolve from a development company to a commercial company with a strong focus on sales growth and profitability. The company has ten distribution partners, including two of the world's fifty largest pharmaceutical companies, covering some 50 markets with a total of approx. 1 billion inhabitants.
Moberg Derma develops innovative products that treat skin diseases such as nail fungus (onychomycosis), atopic dermatitis and actinic keratosis through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma was established in 2006 and has 25 employees. Moberg Derma's share (OMX: MOB) is listed on NASDAQ OMX Stockholm's main list.
For more information, please visit www.mobergderma.com
Top of page »
Oral Care is a dental care company that works with mobile dental care for elderly and
sick people who are unable to go and see the dentist themselves. Oral Care treats some
25,000 patients a year in Sweden, and has been commissioned by nine Swedish county
councils to carry out oral health assessments and to train care staff.
As a result of the company's IT innovation, Mobildent, the company has developed a
unique research platform in collaboration with Karolinska Institutet and researchers
from Astra Zeneca, focusing on the links between deterioration in oral health and effects
on general health.
There is great international interest in Oral Care's method of operating, and
collaboration has been initiated with Japan and Germany. A growing ageing population
that still has its own dentition intact will pose great challenges, in which Oral Care is
way ahead of the game in working preventively and reducing the costs of caring for this
expanding patient group.
For more information, please visit www.oralcare.se
Top of page »
Serendipity Innovation is a privately held venture capital firm and business
incubator whose core business is to create new innovative companies
based on leading academic research. We do this in conjunction with world-
leading scientists, skilled entrepreneurs, and by working closely with potential
customers to ensure that the products and services developed meet the
actual market demand and requirements. Our product development projects
usually involve paying customers. This makes the value creation process
efficient and ensures that resources to create value are allocated where
needed and appreciated from a customer perspective.
Serendipity's key success factor has been the ability to reduce the gap
between research and enterprise, or rather, scientists and entrepreneurs.
We build effective teams with key competences, complementary skills and
personalities, and provide them with effective tools and processes for building
a successful organization.
Our goal is to build companies that are world leaders in their niche. The vision
is to become a world-leading innovation generator and thus a role model for
the transformation of technical knowledge into successful businesses. We
want to achieve this by creating innovative products and services that make
life richer and more enjoyable for people.
For more information, please visit www.serendipityinnovations.com
Top of page »
The world is facing the demographic challenge of a rapidly aging population. In Sweden, the number of
people in working age (aged 20-64) per elderly (80+) has decreased from 35 in 1970 to 12 in 2010 and is
forecasted to reach 7 in 2040. This dependency ratio presents a grim picture of our future capability of caring
for our elderly.
Having this striking development in mind, ACCESS Health International, a not for profit organization
dedicated to improving access to high quality and affordable healthcare worldwide, is creating a platform
for knowledge transfer between countries that are undergoing similar challenges in terms of aging.
Policymakers, business leaders, entrepreneurs and the general public need a better understanding of efforts
in other countries in order to prepare for the new demographic landscape in the best possible way. The
organization was founded by Professor William A. Haseltine.
ACCESS Health International's work encompasses research, knowledge transfer and implementation support
related to health finance, health service delivery and health technology. ACCESS' partners include, among
others, the World Bank, UNICEF, The Rockefeller Foundation, Bill and Melinda Gates Foundation, MacArthur
Foundation, National University of Singapore, Indian School of Business, Stockholm School of Economics,
as well as several private corporations. The organization's offices are located in India, Bangladesh, US,
Singapore, the Philippines and since the beginning of the year, also in Sweden. The Swedish activities are
focused on elderly and chronic care. ACCESS identifies and documents innovation worldwide and works to
transfer the knowledge about good practices.
For more information, please visit www.accessh.org
Top of page »
AliveCor, Inc., headquartered in San Francisco, California, aims to provide medical professionals, patients,
and consumers worldwide with mobile-powered devices, data, and analysis to identify, prevent, and manage
life-altering diseases from anywhere in the world.
As its first offering, AliveCor has developed a disruptively low cost, easy-to-use, clinical-quality ECG heart
monitor for the iPhone 4 and 4S. This single-lead ECG device utilizes the power, display, and communication
capabilities of the iPhone. The medical device snaps onto the iPhone 4 or 4S like a case and wirelessly
communicates with the app on the phone. No pairing between the iPhone and the device is required, as
it uses AliveCor's patent-pending, wireless communication protocol. Physicians and prescribed patients
can take 30-second, up to continuous, rhythm strips. The device is not currently for sale and is awaiting
marketing approval.
For more information, please visit www.alivecor.com
Top of page »
AroCell is in the process of commercializing a new marker for determination of cell growth, which will be
clinically useful for prognosis, monitoring and follow-up of cancer patients.
Cancer is characterized by uncontrolled cell growth. The rate of cell growth is directly linked to the
aggressiveness of the tumor. The uniqueness of the method is therefore that it specifically identifies the
aggressive and fast-growing cancer tumors. Numerous methods for detecting cancer are currently being
employed. All of these markers, including imaging techniques, are based on tumor mass. A marker that
specifically detects tumor cell growth represents an important complimentary tool for monitoring of cancer
treatment
The AroCell test, TK 210 measures the protein thymidine kinase (TK) with a standard laboratory method. TK
is the only marker for cell growth that can be measured directly in an ordinary blood sample. Clinical studies
have proven the clinical value of TK 210 in more than ten different cancer forms. AroCell´s first product will
be launched within the next few months. It will be a test for the prognosis and monitoring of blood cancer.
The second product will be designed for solid tumors, such as prostate and breast cancer. The total market
for cancer diagnostics worldwide is estimated to be approximately 7.8 billion USD in 2012.
For more information, please visit www.arocell.com
Top of page »
BioLamina develops and sells proprietary recombinant laminins that are today used as a coating to culture
human embryonic and iPS cells. Laminins are biological proteins expressed close to all tissue types and
therefore are a natural biological base to culture various cell types including pluripotent stem cells. Because
of the biology, these proteins allow several advantages compared to other coatings. Stem cells are easy to
culture, they grow fast and stay pluripotent when using our recombinant laminins. We have also developed
a technique to create new stem cell lines without killing the embryo, an innovation that can significantly
decrease the ethical problems associated with human embryonic stem cells.
Income from stem cell coatings is the base of our operations today. However, we believe there is even more
potential for some of our new innovations in other business areas. Using the method to make new stem cell
lines, we can also make true stem cell banks for IVF-fertilized children, a business we want to expand to. We
also have scientific proof that laminins can induce hair growth, another area our proprietary laminins can be
used for.
For more information, please visit www.biolamina.com
Top of page »
Diabetes Tools Sweden AB, founded in 2005. The company is devoted to development of software solutions
for Diabetes Care within the healthcare management services aspects of patient motivation and education,
by an integrated smartphone-cloud-web and based system for monitoring, analysis and classification.
By the implementation of an engineering driven approach, Diabetes Tools offers innovative products
by incorporating new methods to enhance the understanding and awareness of alternative solutions in
combating the diabetes epidemic. These products and self-care tools are aimed to provide assistance to
the patient in the daily treatment and also as instruments of monitoring and risk control for the health care
provider. By organizing the exchange of information between these parties, Diabetes Tools creates the basis
for an effective treatment strategy that promote patient health and reducing health care costs in the short
and long term.
Diabetes Tools' objective is to commercialize a broad and unique product portfolio and to become an
international leader in diabetes specific lifestyle change management.
For more information, please visit www.diabetestools.se
Top of page »
Insulution has developed an innovation that can increase the quality of life for insulin-injecting diabetics. The
product is called Daily Dose, and is a system consisting of a holder that can fit three exceptionally small and
specially designed pre-fillable insulin syringes. There are a number of benefits of the Daily Dose - especially
in certain situations - compared to the conventional insulin syringe or -pen; the most important being that it
is small and convenient, discreet to inject and the fact that one only needs to carry the insulin doses needed
for the day. The risk of incorrect dosage is also minimized, the used needles are securely disposed of, and it is
easy to keep track of which doses that have been taken.
According to our calculations, the total number of insulin-injections worldwide is approximated to 100
billion per year, and is steadily increasing. Insulution has signed contracts with several distributors in
different regions, and is in the middle of a global product launch in a number of markets.
For more information, please visit www.insulution.se
Top of page »
MedUniverse was launched in 2009 and is a community where doctors can discuss important clinical and
career issues with colleagues. Doctors on MedUniverse can use the platform to start their own networks,
share documents and exchange advice, build their own digital profile and maintain contact with colleagues
and former classmates.
The business model is based on targeted advertising, events and market research. In 2012 MedUniverse is
launching Simpatico ™ - simulated patient contact online.
MedUniverse is part of an international alliance of online doctor communities called Networks in Health.
For more information, please visit www.meduniverse.se
Top of page »
Admissions for congestive heart failure consume about 44% of Medicare's hospitalization budget yearly. CHF
is also the most common 30-day readmission diagnosis in the USA, costing between $10 and $12 billion each
year. To address this problem, coordinated care programs with telephony and visiting nurse follow up have
shown promise.
PillJogger seeks to augment these programs by developing a tablet base transitional care solution for
patients, integrating PillJogger's core functionality for adherence. We've designed a cross-cultural platform
that is simple, intuitive, icon driven and entertaining.
Each module is designed on a basic template with individual features selected by the sponsoring
organization (payer or hospital system). Such features may include tap- to-schedule functionality (for
appointments, refills, physical therapy etc), video and/or audio chat with caregivers, voice transcription,
and wireless connectivity with monitoring devices such as scales, blood pressure cuffs, spirometry and
glucometers. Besides medication events, we remind about follow-up appointments and we can update the
care plan as soon as it is changed in the electronic health record.
Additional modules for post-MI, pneumonia, asthma/copd and post coronary interventions are also in
development.
For more information, please visit www.pilljogger.com
Top of page »
Q-linea, an Uppsala based biotechnology company combine innovative proprietary molecular toolkit with
engineering expertise to provide novel solutions for detection and identification of biomolecules.
Q-linea will provide to the physician both the pathogen identity and antibiotic susceptibility pattern within
ours compared to current state-of-the-art that delivers answers in days.
This technology breakthrough will greatly increase the capabilities for health care professionals to select
proper treatment for patients, and reduce the overuse of antibiotics.
The company is also developing systems aimed for detection and identification of bacteria, spores, viruses
and toxins for use in biodefense and biosafety applications. Using our amplified single molecule detection
technology, we are able to detect very low amounts of agents within a short time frame, while having a high
specificity and the ability to detect multiple agents simultaneously.
For more information, please visit www.qlinea.com
